Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Director | June 24, 2026 | June 26, 2026 |
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | June 05, 2026 | June 09, 2026 |
| Carisma Therapeutics Inc.CARM · Entity 74418 | Director | June 26, 2024 | June 27, 2024 |
| Codiak BioSciences, Inc.CDAK · Entity 114958 | Director | February 17, 2021 | February 17, 2021 |
| NextCure, Inc.NXTC · Entity 7461 | Director | June 11, 2020 | June 15, 2020 |
| Oncorus, Inc.ONCR · Entity 112213 | Director | October 01, 2020 | October 01, 2020 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 07, 2024 | February 09, 2024 |
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director | June 12, 2025 | June 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 24, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 111,548 |
Reported balance
After 2026-06-24 transaction · row 1
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 15,527 · Balance 111,548 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2036-06-23 | Direct | 22,714 |
Reported balance
After 2026-06-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-24 · Grant · Acquired 22,714 · Balance 22,714 F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
CRISPR Therapeutics AG
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05 | Direct | 13,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.
Carisma Therapeutics Inc.
Report date June 26, 2024 · Filed June 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2034-06-26 | Direct | 19,350 |
Reported balance
After 2024-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-26 · Grant · Acquired 19,350 · Balance 19,350 F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director.
Codiak BioSciences, Inc.
Report date February 17, 2021 · Filed February 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,761 |
Reported balance
After 2021-02-17 transaction · row 1
1 source rowRow 1 · 2021-02-17 · Purchase · Acquired 4,761 · Balance 4,761 |
NextCure, Inc.
Report date June 11, 2020 · Filed June 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.13 · Expires 2030-06-10 | Direct | 14,250 |
Reported balance
After 2020-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-11 · Grant · Acquired 14,250 · Balance 14,250 F1: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders.
Oncorus, Inc.
Report date October 01, 2020 · Filed October 01, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2026-04-26 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2026-08-28 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 27,200 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 27,200 · Balance 27,200 F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date.
Syndax Pharmaceuticals Inc
Report date February 07, 2024 · Filed February 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,836 |
Reported balance
After 2024-02-07 transaction · row 1
1 source rowRow 1 · 2024-02-07 · Grant · Acquired 17,000 · Balance 34,836 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Werewolf Therapeutics, Inc.
Report date June 12, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11 | Direct | 27,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 27,000 · Balance 27,000 F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 26, 2026 20:22 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 22,714 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0001628280-26-045786 · wk-form4_1782505358.xml · derivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,714 Underlying: Common Stock · 22,714 shares Expires 2036-06-23 F2 · derivative.exercise_date: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:22 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 15,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-045786 · wk-form4_1782505358.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,548 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $51.84 | $0.00 |
DisclosureSEC source: 0001193125-26-264285 · ownership.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. Read SEC document |
| March 06, 2026 Filed Mar 9, 2026 20:05 UTC | ARVINAS, INC. ARVN · Entity 5355 | PurchaseCommon Stock | 20,000 | $13.40 | $268,070.00 |
DisclosureSEC source: 0001628280-26-016003 · wk-form4_1773086718.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,021 F1 · price: The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.364 to $13.45, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 13:16 UTC | ARVINAS, INC. ARVN · Entity 5355 | PurchaseCommon Stock | 30,000 | $7.57 | $227,010.00 |
DisclosureSEC source: 0001628280-25-042536 · wk-form4_1758719774.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,021 F1 · price: The purchase price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.65, inclusive. The reporting person undertakes to provide to Arvinas, Inc., any security holder of Arvinas, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 25, 2025 Filed Jun 28, 2025 01:14 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 23,105 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001655759-25-000122 · wk-form4_1751073270.xml · derivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,105 Underlying: Common Stock · 23,105 shares Expires 2035-06-24 F2 · derivative.exercise_date: This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| June 25, 2025 Filed Jun 28, 2025 01:14 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 16,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000122 · wk-form4_1751073270.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,021 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:10 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086173 · ownership.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $38.57 | $0.00 |
DisclosureSEC source: 0000950170-25-083274 · ownership.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 16:54 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 19,350 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001104659-24-075719 · tm2418415-2_4seq1.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,350 Underlying: Common Stock · 19,350 shares Expires 2034-06-26 F1 · derivative.exercise_date: The shares underlying this option vest with respect to all of the shares underlying such option on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to the non-employee director's continued service as a director. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:35 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017658 · form4-06202024_040613.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2034-06-16 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| May 29, 2024 Filed May 31, 2024 21:51 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 9,070 | $0.00 Strike: $33.90 | $0.00 |
DisclosureSEC source: 0001655759-24-000083 · wk-form4_1717192298.xml · derivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,070 Underlying: Common Stock · 9,070 shares Expires 2034-05-28 F2 · derivative.exercise_date: This option award was granted on May 29, 2024. The shares underlying the award shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| May 29, 2024 Filed May 31, 2024 21:51 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 5,899 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-24-000083 · wk-form4_1717192298.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,996 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on May 29, 2024 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| May 24, 2024 Filed May 24, 2024 23:49 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.88 | $0.00 |
DisclosureSEC source: 0000950170-24-064845 · ownership.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-23 F1 · derivative.exercise_date: The option was granted on May 24, 2024. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001216 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,836 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 10:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 52,855 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-23-006262 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,855 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.expiration_date: This option is fully vested. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 10:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 52,855 | $18.27 | $965,401.86 |
DisclosureSEC source: 0001562180-23-006262 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,836 F1 · kind: Following the sales reported in this Form 4, the Reporting Person has a total of 559,142 options to purchase shares of common stock that are vested and immediately exercisable and a total of 247,875 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $18.02 to $18.41. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 10:50 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 52,855 | $8.77 | $463,538.35 |
DisclosureSEC source: 0001562180-23-006262 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 13:23 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 52,855 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-23-005845 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,855 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 13:23 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 52,855 | $20.40 | $1,078,067.58 |
DisclosureSEC source: 0001562180-23-005845 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,836 F1 · kind: Following the sales reported in this Form 4, the Reporting Person has a total of 601,143 options to purchase shares of common stock that are vested and immediately exercisable and a total of 258,729 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $20.11 to $20.71. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 13:23 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 52,855 | $8.77 | $463,538.35 |
DisclosureSEC source: 0001562180-23-005845 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 21:07 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 13,200 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0000899243-23-016389 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,200 Underlying: Common Stock · 13,200 shares Expires 2033-06-20 F1 · derivative.exercise_date: The option was granted on June 21, 2023. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:27 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 12,787 | $0.00 Strike: $30.33 | $0.00 |
DisclosureSEC source: 0001655759-23-000065 · wk-form4_1687296466.xml · derivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,787 Underlying: Common Stock · 12,787 shares Expires 2033-06-14 F2 · derivative.exercise_date: This option award was granted on June 15, 2023. The shares underlying the award shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:27 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 4,121 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-23-000065 · wk-form4_1687296466.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,097 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 15, 2023 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 15, 2024 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 24,582 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-23-005057 · primarydocument.xml · derivative · entry 6 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,582 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 28,273 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-23-005057 · primarydocument.xml · derivative · entry 5 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,273 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 28,273 | $21.18 | $598,796.69 |
DisclosureSEC source: 0001562180-23-005057 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,836 F1 · kind: Following the sales reported in this Form 4, the Reporting Person has a total of 643,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 269,583 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $20.94 to $21.58. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 24,582 | $21.18 | $520,624.64 |
DisclosureSEC source: 0001562180-23-005057 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,109 F1 · kind: Following the sales reported in this Form 4, the Reporting Person has a total of 643,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 269,583 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $20.94 to $21.58. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 28,273 | $8.77 | $247,954.21 |
DisclosureSEC source: 0001562180-23-005057 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 21:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 24,582 | $6.38 | $156,833.16 |
DisclosureSEC source: 0001562180-23-005057 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,418 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:27 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 27,200 | $0.00 Strike: $11.66 | $0.00 |
DisclosureSEC source: 0001209191-23-036318 · doc4.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,200 Underlying: Common Shares · 27,200 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option will vest in equal monthly installments over twelve (12) months from the date of grant, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 18:11 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 38,700 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001104659-23-069492 · tm2318219-1_4seq1.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,700 Underlying: Common Stock · 38,700 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares underlying this option vest over three years in equal monthly installments following June 6, 2023, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 52,855 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-23-004032 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,855 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 52,855 | $21.41 | $1,131,477.56 |
DisclosureSEC source: 0001562180-23-004032 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,836 F1 · kind: Following the sales reported in this Form 4, the Reporting Person has a total of 685,144 options to purchase shares of common stock that are vested and immediately exercisable and a total of 280,438 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $20.78 to $22.99. Read SEC document |
| May 09, 2023 Filed May 10, 2023 20:11 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 52,855 | $6.38 | $337,214.90 |
DisclosureSEC source: 0001562180-23-004032 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:03 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 52,855 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-23-003521 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,855 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:03 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 52,855 | $19.53 | $1,032,237.01 |
DisclosureSEC source: 0001562180-23-003521 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,836 F1 · kind: Following the sales reported in this Form 4, the Reporting Person has a total of 727,145 options to purchase shares of common stock that are vested and immediately exercisable and a total of 291,292 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $19.28 to $20.11. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:03 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 52,855 | $6.38 | $337,214.90 |
DisclosureSEC source: 0001562180-23-003521 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Option (Right to Buy) · Derivative | 52,854 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-23-002770 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,854 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 52,854 | $22.53 | $1,190,673.77 |
DisclosureSEC source: 0001562180-23-002770 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 822,000 options to purchase shares of common stock that are vested and immediately exercisable and a total of 302,146 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $22.05 to $23.10. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:42 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 52,854 | $6.38 | $337,208.52 |
DisclosureSEC source: 0001562180-23-002770 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:21 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 34,189 | Not disclosed Strike: $1.46 | Not disclosed |
DisclosureSEC source: 0001104659-23-030746 · tm238905-1_4seq1.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,189 Underlying: Common Stock · 34,189 shares Expires 2031-03-31 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." F4 · derivative.exercise_date: The shares underlying this option vest over four years, with 25% of the shares vested on April 1, 2022 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:21 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantStock Option (Right to Buy) · Derivative | 63,310 | Not disclosed Strike: $0.68 | Not disclosed |
DisclosureSEC source: 0001104659-23-030746 · tm238905-1_4seq1.xml · derivative · entry 2 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,310 Underlying: Common Stock · 63,310 shares Expires 2030-07-23 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." F3 · derivative.exercise_date: The shares underlying this option vest over four years, with 25% of the shares vested on July 24, 2021 and the remaining shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 21:21 UTC | Carisma Therapeutics Inc. CARM · Entity 74418 | GrantCommon Stock | 12,175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-030746 · tm238905-1_4seq1.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,175 F1 · price: In connection with the merger of Sesen Bio, Inc. ("Sesen Bio") and private company CARISMA Therapeutics Inc. ("Carisma"), pursuant to the Agreement and Plan of Merger and Reorganization dated as of September 20, 2022, as amended by the First Amendment thereto dated as of December 29, 2022 and the Second Amendment thereto dated as of February 13, 2023 (as amended, the "Merger Agreement"), which closed on March 7, 2023 (the "Closing"), (i) each share of Carisma common stock was converted into the right to receive 1.8994 shares of Sesen Bio common stock (the "Exchange Ratio") and (ii) each outstanding and unexercised option to purchase shares of Carisma common stock converted into an option to purchase shares of Sesen Bio common stock, with necessary adjustments to reflect the Exchange Ratio but otherwise the same terms and conditions. F2 · price: The Exchange Ratio gives effect to the 1-for-20 reverse stock split of Sesen Bio's common stock. On the Closing date, the closing price of Sesen Bio common stock was $0.6288 (unadjusted). Upon Closing, Sesen Bio was renamed "Carisma Therapeutics Inc." Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 52,854 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-23-001117 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,854 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 52,854 | $26.83 | $1,417,908.97 |
DisclosureSEC source: 0001562180-23-001117 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 811,146 options to purchase shares of common stock that are vested and immediately exercisable and a total of 313,000 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $26.49 to $27.91. Read SEC document |
| February 06, 2023 Filed Feb 8, 2023 21:49 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionCommon Stock | 52,854 | $6.38 | $337,208.52 |
DisclosureSEC source: 0001562180-23-001117 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:02 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 32,000 | $28.55 Strike: $28.55 | $913,600.00 |
DisclosureSEC source: 0001562180-23-000955 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| September 20, 2022 Filed Sep 21, 2022 20:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | Exercise / conversionStock Options (Right to buy) · Derivative | 59,649 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-22-006788 · primarydocument.xml · derivative · entry 6 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,649 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| September 20, 2022 Filed Sep 21, 2022 20:18 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 59,649 | $23.25 | $1,387,012.23 |
DisclosureSEC source: 0001562180-22-006788 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 774,958 options to purchase shares of common stock that are vested and immediately exercisable and a total of 370,042 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $22.60 to $23.75 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.